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Aim: Methotrexate (MTX) is an antifolate agent that acts inhibiting purine and pyrimidine synthesis. The objective of the study 
was to evaluate the viability of Hep-2 human laryngeal cancer cells to the treatment with MTX chemotherapy in vitro. Methods: 
Cultured Hep-2 cells were treated with 0.25, 25.0 and 75 μM MTX for 24 h, and their viability was evaluated with Bcl-2-FITC 
antibody in flow cytometry. Results: The numbers of viable Hep-2 cells after 24 h treatment with 0.25, 25.0 and 75.0 uM MTX 
were 85.43%, 22.46% and 8.42%, respectively (p < 0.05). Therefore, MTX possesses a dose-dependent effect on viability 
of Hep-2 cells in vitro. Conclusion: The highest MTX concentration is associated with highest tumor cell sensitivity of human la-
ryngeal cancer cells of Hep-2 line.
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Head and neck cancer �HNC� includes tumors 
of pharynx� oral cavity and larynx. The treatment 
of these tumors may �e surgery� radiotherapy and 
chemotherapy [���]. Methotrexate ����-diamino�N��-
methylpteroyl glutamic acid� �MTX� is an antiprolifera-
tive and immunosuppressive chemotherapeutic agent 
widely used against a �road spectrum of diseases� 
including HNC [�� 5]. It acts via inhi�ition of the synthe-
sis and conversion of folate derivatives responsi�le for 
providing methyl groups for the nucleotides synthesis 
and �NA methylation reactions [����]. Although che-
motherapy presents good results� tumors may develop 
resistance to antifolate agents. A num�er of factors 
are critical for a favora�le clinical outcome for MTX 
therapy� in particular acute toxicity� side effects� and 
drug resistance development [5� �����]. The current 
study was undertaken to evaluate in vitro the human 
larynx squamous cell carcinoma Hep-� cell line sen-
sitivity to the MTX treatment. The cell line was cultured 
in �ul�ecco Medium ��-MEN ����8 medium� Culti-
la��� supplemented with ��% fetal �ovine serum �FBS� 
Cultila��� � μM glutamine �Cultila��� ��� U/ml of peni-
cillin� ��� U/ml of streptomycin� � μM sodium pyruvate 
�Sigma�Aldrich� and � μM non-essential amino acid 
�Sigma�Aldrich� in a humidified 5% CO�/�5% air at-
mosphere at �� °C. MTX concentrations of �.�5 μM� 
�5 μM� and �5 μM were calculated according to Pai 
et al. [��]. Hep-� cells were incu�ated with the men-
tioned MTX concentrations for �� h� while the control 
cells were cultured in MTX-free medium. Cell via�ility 
was measured �y flow cytometry �FACS cali�er- Bec-
ton �ickinson Immunocytometry Systems� San José� 
USA� with dou�le staining with fluorescein isothiocya-
nate �FITC�/Bcl-� according to manufacturer’s manual 
�Santa Cruz Biotechnology� Inc�. Each experiment was 
performed in triplicate. The normal distri�ution of the 
samples was verified with Normality tests �Shapiro — 
Wilk’s test and Kolmogorov — Smirnov test�. Statistical 
analysis was performed �y nonparametric methods 
�ased upon the comparison �etween the groups. 
The effects for MTX concentrations in the cell via�ility 
were evaluated independently �y Kruskal-Wallis test 
�Control group x ���5 uM MTX concentration / Control 
group x �5 uM MTX concentration / Control group 
x �5 uM MTX concentration�. For comparison of the 
varia�les �etween groups exposed with MTX and 
free-MTX group we used the Mann — Whitney test. 
The Spearman correlation degree �etween varia�les 
of interest was calculated �y Spearman test. 
The results of flow cytometry analysis with FITC/
Bcl-� dou�le staining showed that ��.�% of control cells 
were vital� while the num�ers of via�le Hep-� cells after 
�� h treatment with �.�5; �5.� and �5.� uM MTX were 
85.��; ��.�� and 8.��%� respectively �Figure� Ta�le� �p 
< �.�5�. The Shapiro — Wilk’s test indicated that there 
was a normal distri�ution for the groups �p = �.�8��. 
The Kolmogorov — Smirnov test confirmed that all 
samples presented significance level of 5% for groups 
�K-S = �.�8�; p = �.��8� �Ta�le�. The Kruskal-Wallis test 
indicated a significant effect of MTX in the cell via�ility 
�H = �.��� p = �.����. The value of Mann — Whitney test 
showed significant results �p= �.�����. The Spearman 
correlation �etween frequencies of cells exposed with 
MTX and unexposed showed an interaction �etween 
these cells �r = �.5��. Our study confirmed that cells 
were more sensitive and �ecame less resistant to the 
MTX chemotherapy as dose was increasing. More-
over� there was a correlation �etween cells exposed 
frequencies with MTX and unexposed cells; literature 
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data show MTX concentration correlates with drug 
therapeutic efficacy [��]. These results suggest that 
MTX has su�stantial antiproliferative activity and is used 
effectively as a chemotherapy agent in the treatment 
for solid-organ neoplasms and the treatment is more 
efficient when the dose is increased. However� the pi-
lot study of Pai et al. [��] that evaluated the sensi�ility 
of oral cancer cells to MTX in vitro and its association 
with clinical response to MTX in oral cancer showed 
that there is differential sensitivity to MTX among the 
various tumor cells in the in vitro assay� and these data 
had significant correlation when compared with clinical 
outcome for � out of �� patients. MTX is an antimeta�o-
lite� analogous to folate� that competitively inhi�its di-
idrofolatoredutase ��HFR� enzyme activity� essential for 
nucleotides purines and thymidylic acid �iosynthesis� 
interfering with �NA synthesis. [��� �8� ��]. Although 
we found that MTX treatment is highly effective in HNC 
cells� data confirm that high-dose MTX schemes may 
arrest normal epidermal cell proliferation and cause 
direct cell toxicity [��]. Toxicity is increased �y folic 
acid deficiency or �y medications such as �ar�iturates 
and nitrofurantoin� which impair folic acid a�sorption 
[��� ��]. However� it has �een documented that folic 
acid �� to 5 mg/day� supplementation helps to prevent 
MTX associated toxicities and concomitant use of ei-
ther folic acid with methotrexate has no impact on the 
therapeutic efficacy of MTX in multiple clinical trials and 
meta-analyses [��� ��]. 
Figure. Flow cytometry analysis of Hep-� cells treated with �.�5� 
�5 and �5 mM MTX �b� c� d respectively� and control cells �a�. 
The cells in the “R�” �lock are cells non-via�le and cells in the 
“R�” are via�le. Cell via�ility was evaluated �y dou�le staining 
with fluorescein isothiocyanate �FITC� la�el Bcl-� ����: sc-5���; 
Pink cells are via�le� �lue cells — non-via�le 
Table. Viability of Hep 2 cells treated with MTX for 24 h
MTX dose Concentration Viable cells, M ± SD
Control group 9,260 ± 50
0.25 mM 7,910 ± 26*
25 mM 2,080 ± 44*
75 mM 780 ± 30*
* The difference is significant compared to the control (p < 0.05).
Research a�out chemosensitivity is important 
to screen new therapeutic agents� identify patterns 
of sensi�ility for different tumor types� to select 
chemotherapy regimens to individual patients and 
improvement in life quality [��]. We conclude that the 
highest MTX concentration is associated with highest 
tumor cells sensi�ility; as a consequence� the know-
ledge of the drug sensi�ility can do significant impact 
in decision-making and treatment.
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